View in EDS

Population-based survival of penile cancer patients in Europe and the United States of America: No improvement since 1990

Saved in:
Bibliographic Details
Title: Population-based survival of penile cancer patients in Europe and the United States of America: No improvement since 1990
Authors: Verhoeven, R H A, Janssen-Heijnen, M L G, Saum, K U, Zanetti, R, Caldarella, A, Holleczek, B, Brewster, D H, Hakulinen, T, Horenblas, S, Brenner, H, Gondos, A, EUNICE Survival Working Group
Contributors: Usel, Massimo
Source: European Journal of Cancer, Vol. 49, No 6 (2013) pp. 1414-21
Publisher Information: Elsevier BV, 2013.
Publication Year: 2013
Subject Terms: Adult, Male, Adolescent, Risk Assessment, Penile Neoplasms/epidemiology/mortality, Europe/epidemiology, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Risk Assessment/methods/statistics & numerical data, Humans, Registries, Penile Neoplasms, ddc:613, Aged, Survival Rate/trends, Registries/statistics & numerical data, SEER Program/statistics & numerical data, Middle Aged, United States/epidemiology, Survival Analysis, United States, 3. Good health, Population Surveillance/methods, Europe, Survival Rate, Population Surveillance, Regression Analysis, SEER Program
Description: Penile cancer is a rare neoplasm in Western countries, and detailed studies on trends in population-based survival of penile cancer have never been published before. We examined population-based trends in survival in Europe and the United States of America (USA).Data from 3297 European and 1820 American penile cancer patients, contributed by 12 European cancer registries and the Surveillance, Epidemiology, and End Results (SEER) Program of the USA were included in this study. Period analysis techniques were used to examine relative survival trends overall, as well as for four geographic regions in Europe, and for the age groups 15-54, 55-64, 65-74 and 75+ for both populations between 1990-1995 and 2002-2007. Survival trends were assessed in a multiple regression model of relative excess risk including period of diagnosis, age and continent.The 5-year relative survival of penile cancer patients increased statistically non-significantly from 65% to 70% in Europe and decreased (significantly) from 72% to 63% in the USA. Trends in age-specific 5-year relative survival did not find any significant improvement in either Europe or the USA. The multiple regression analysis confirmed the lack of survival trend, and found significantly higher relative excess risk with age, and, apparently due to lower survival before 2002-2007, higher risk in Europe.Survival for penile cancer patients has not improved in either Europe or the USA since at least 1990. The reasons for the decrease of survival in the USA remain unknown and to be explored. Stronger international cooperation in clinical research may be important to facilitate clinical progress in treatment and thereby improvement of survival of this rare malignancy.
Document Type: Article
File Description: application/pdf
Language: English
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2012.10.029
Access URL: https://pubmed.ncbi.nlm.nih.gov/23231984
https://archive-ouverte.unige.ch/unige:44642
https://www.sciencedirect.com/science/article/pii/S0959804912008635
https://europepmc.org/abstract/MED/23231984
https://mdanderson.elsevierpure.com/en/publications/population-based-survival-of-penile-cancer-patients-in-europe-and
http://www.sciencedirect.com/science/article/pii/S0959804912008635
https://www.ncbi.nlm.nih.gov/pubmed/23231984
https://archive-ouverte.unige.ch/unige:44642
Rights: Elsevier TDM
Accession Number: edsair.doi.dedup.....ad8bebf5365af770d3ae69091bb82997
Database: OpenAIRE
Description
Abstract:Penile cancer is a rare neoplasm in Western countries, and detailed studies on trends in population-based survival of penile cancer have never been published before. We examined population-based trends in survival in Europe and the United States of America (USA).Data from 3297 European and 1820 American penile cancer patients, contributed by 12 European cancer registries and the Surveillance, Epidemiology, and End Results (SEER) Program of the USA were included in this study. Period analysis techniques were used to examine relative survival trends overall, as well as for four geographic regions in Europe, and for the age groups 15-54, 55-64, 65-74 and 75+ for both populations between 1990-1995 and 2002-2007. Survival trends were assessed in a multiple regression model of relative excess risk including period of diagnosis, age and continent.The 5-year relative survival of penile cancer patients increased statistically non-significantly from 65% to 70% in Europe and decreased (significantly) from 72% to 63% in the USA. Trends in age-specific 5-year relative survival did not find any significant improvement in either Europe or the USA. The multiple regression analysis confirmed the lack of survival trend, and found significantly higher relative excess risk with age, and, apparently due to lower survival before 2002-2007, higher risk in Europe.Survival for penile cancer patients has not improved in either Europe or the USA since at least 1990. The reasons for the decrease of survival in the USA remain unknown and to be explored. Stronger international cooperation in clinical research may be important to facilitate clinical progress in treatment and thereby improvement of survival of this rare malignancy.
ISSN:09598049
DOI:10.1016/j.ejca.2012.10.029